Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025
Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, expectations were $-0.35.
Christopher C. Gibson: Hello, and welcome, everybody, to Recursion’s Q2 2025 Earnings Call. My name is Chris Gibson, and I’m the Co-Founder and CEO of Recursion. And I’m excited to share with you today some of the latest updates on our company as we drive forward to decode...
